Alto Neuroscience FY2024 net loss $61.4M; cash $169M; two directors departing

Alto Neuroscience, Inc.

Net loss $61.4M for FY2024 vs $36.3M in 2023; R&D expense $47M, G&A $21.6M.
Cash and equivalents $169M as of Dec 31, 2024; expected to fund operations into 2028.
Directors Jeff Chen and Maha Radhakrishnan will not stand for re-election at 2025 annual meeting; board size to shrink from 7 to 5.
ALTO-300 Phase 2b MDD trial interim analysis positive; topline results expected mid-2026.
ALTO-203 Phase 2 MDD trial enrollment complete; topline data expected Q2 2025.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Maha Radhakrishnan

Director

ANRO · Alto Neuroscience, Inc.

Filed: March 20, 2025, 7:59 PM ET

Also on March 17, 2025, Maha Radhakrishnan, M.D. informed the Company's board of directors (the "Board") that she will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.

Departed

Jeff (Po Yu) Chen

Director

ANRO · Alto Neuroscience, Inc.

Filed: March 20, 2025, 7:59 PM ET

On March 17, 2025, Jeff (Po Yu) Chen, Ph.D. informed the Company's board of directors (the "Board") that he will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Maha Radhakrishnan departed as Director at Alto Neuroscience, Inc..

Action: will not stand for re-election
Role: Director

Exact text from the filing

Also on March 17, 2025, Maha Radhakrishnan, M.D. informed the Company's board of directors (the "Board") that she will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeff (Po Yu) Chen departed as Director at Alto Neuroscience, Inc..

Action: will not stand for re-election
Role: Director

Exact text from the filing

On March 17, 2025, Jeff (Po Yu) Chen, Ph.D. informed the Company's board of directors (the "Board") that he will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.

View on SEC.gov

Alto Neuroscience, Inc. filing history →

Source: SEC EDGAR

accession 0001999480-25-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.